TheraRadar

Briefs tagged "Sanofi"

1 brief

AbbVie Amgen Arvinas BMS Biogen CNS CRISPR Therapeutics Eisai Eli Lilly FDA IBD IGF-1R J&J Merck Novartis Pfizer Regeneron Roche Sandoz Sanofi TL1A Takeda Vertex autoimmune biosimilars bispecific cardiovascular competitive landscape drug development gene therapy genetics immunotherapy metabolic oncology ophthalmology patent cliff protein degradation rare disease regulatory
8 min read

TL1A: The Target Behind the $18 Billion Bet

Every approved IBD drug fights inflammation. None of them touch fibrosis. TL1A does both.

30% of Crohn's disease patients will need surgery within ten years of diagnosis - not because their drugs failed to control inflammation, but because no approved drug stops the scar tissue that narrows their bowel. TL1A is the first target that could change that. Here is the biology behind the $18 billion bet.

Read the full brief
autoimmunedrug developmentTL1AMerckRoche

Get the next Brief in your inbox — free

Every drug has multiple stories. Most never get told. One brief every week. No spam.

Archive lives at /briefs/. Unsubscribe anytime.